

Growth of hPSCs using functional hECM

1

Growth of Human Pluripotent Stem Cells using Functional Human ECM

Andres Sanz-Garcia^{1,2}, Miodrag Stojkovic^{3,4}, and Carmen Escobedo-Lucea^{1,2}

1. *Tissue Engineering Group. Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Finland*

2. *Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University TWINS. Tokyo, Japan*

3. *SPEBO Medical, Leskovac, Serbia*

4. *Department of Human Genetics, Faculty of Medicine, University of Kragujevac, Serbia*

Correspondence: *Carmen Escobedo-Lucea, PhD*

1 Tissue Engineering Group. Centre of Drug Research (CDR). Division of Pharmaceutical Biosciences. Faculty of Pharmacy. University of Helsinki, Viikinkaari 5 E (P.O. Box 56), 00014 Helsinki, Finland

2 Institute of Advanced Biomedical Engineering and Science. Tokyo Women's Medical University TWINS. 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan

carmen.escobedo-lucea@helsinki.fi

The final publication is available at link.springer.com

[Human Embryonic Stem Cell Protocols](http://link.springer.com/protocol/10.1007/7651_2014_154)

http://link.springer.com/protocol/10.1007/7651_2014_154

38 **Abstract**

39 The use of animal products in the derivation and maintenance of human pluripotent stem cells
40 (hPSCs) limits their possible applications in research and in clinics. Thus, one of the major goals
41 in regenerative medicine is the establishment of animal-free conditions to support the culture and
42 differentiation of human stem cells. Human fibroblasts produce an extracellular matrix (ECM)
43 which can be extracted without the use of detergents, sterilized, and then used to coat tissue
44 culture plates.

45 We have shown that human embryonic stem cells (hESCs) grown on this matrix maintain their
46 pluripotency in the presence of medium conditioned by fibroblast cells, and that these cells
47 maintain expression of surface proteins (SSEA4, Tra1-60, Tra1-81), alkaline phosphatase activity
48 and specific intracellular markers (Nanog, Oct-4, Tert, FoxD3) in hESCs. This growth system
49 reduces exposure of hPSCs to feeder layers and animal ingredients, thereby limiting the risk of
50 pathogenic contamination and additionally, facilitating their manipulation. Herein we present an
51 improved version of our previous protocol for extracting ECM from human foreskin fibroblast
52 using a different buffer. Our new hypotonic shock method is detergent-free, reduces costs, and
53 preserves the integrity of the extracted ECM. This improved protocol has been validated for
54 undifferentiated-state hPSC maintenance (more than 40 passages), stem cell differentiation and
55 for cell migration assays.

56
57 **Keywords:** human embryonic stem cells; human pluripotent stem cells, *in vitro* growth;
58 extracellular matrix, hypo-osmotic lysis buffer

59

60

61 **1. Introduction**

62 The stem cell biology field is continually transforming, especially in recent years with the
63 introduction of several validated protocols for obtaining human-induced pluripotent stem cells
64 (hiPSCs) (1,2), which have created new avenues for studying different diseases and regenerative
65 medicine applications. Several human embryonic stem cell (hESC) and hPSC lines have been
66 derived and grown using mouse feeder layers, Matrigel®, or other animal reagents (3,4).
67 However, recent successes using pluripotent stem cell (PSC) derivatives in clinical trials (5,6)
68 have emphasized the need for improved quality standards before these derivatives are applied in
69 cell therapies. In particular, new culture methods must be developed that circumvent the need for
70 animal products because these might provoke infections or immune rejection following
71 transplantation into patients (7). Thus, chemically defined culture systems that are devoid of
72 nonhuman substances will greatly facilitate the use of human stem cells (hSCs) in therapies.

73 Extracellular matrix (ECM) modulates cellular adhesion processes and signaling inside stem cell
74 niches and is essential for maintaining their structure and supportive qualities (8,9). An attractive
75 alternative to the use of feeder cells, and the complications associated with them, is the
76 development of an animal-free ECM, and there would be many advantages to maintaining PSCs
77 on such supports. Indeed, undefined mixtures of natural and synthetic matrix proteins are already
78 used as a coating for in vitro human stem cell culture (10), but unfortunately, most of these
79 reagents are cost-prohibitive for many laboratories. Decellularization procedures are traditionally
80 used to isolate ECM from cells and organs (11), facilitating remodeling in animal models and
81 humans. However, the procedures used to remove the cells, especially detergent-based methods,
82 can alter the native structure of the ECM (12,13).

83 We previously published a protocol which allows long-term growth of undifferentiated hESCs on
84 human functional foreskin ECM (hffECM), extracted by using RIPA buffer and cultured using
85 human foreskin conditioned medium, in the *Methods in Molecular Biology* series (14). Here we
86 present a modification of our previous protocol which replaces RIPA with a simple, low-cost
87 hypotonic buffer without detergents. The hffECM obtained is capable of maintaining the
88 pluripotency of hESCs for more than 40 passages (12). Additionally, our hffECM has also been
89 validated as a coating for directed-differentiation experiments by using both hESCs and
90 mesenchymal stem cells (MSCs) and as a basis for cell migration studies (12,15,16).

92 **2. Materials**

93 **2.1. Culture of Human Foreskin Fibroblast for Derivation of Conditioned Media and Human**
94 **Functional Foreskin-derived Extracellular Matrix (hffECM)**

- 95 1. Human foreskin fibroblasts (ATCC, Catalogue No. CRL-2429, Passages 11--18; *see Note 1*).
96 2. Iscove's medium (Sigma, St. Louis, MO), supplemented with 10% human serum (HS), 1%
97 Glutamax (GIBCO, Invitrogen, Carlsbad, CA).
98 3. Gelatin (1.5%; Sigma). In a sterile bottle, add embryo-tested water (Sigma) to gelatin. Warm
99 the mixture to 37° C in a water bath using a shaker. Store at 4° C or make aliquots and keep them
100 frozen at -20° C. These aliquots can be stored for up to 6 months. Before proceeding with tissue
101 culture, thaw the aliquots and dilute them to 0.01% with sterile Dulbecco's PBS (DPBS)
102 (Invitrogen). Pass the solution through a 0.22 µm filter (Nalgene, Hereford, UK). Coat the culture
103 surfaces by pipetting 1 mL/well into 6-well plates (BD, San Jose, CA) or 12 mL into a 75 cm²
104 flask (Iwaki, Ibaraki, Japan). Allow the gelatin to settle at 37° C for 30 min. Plates may be used
105 immediately or stored at 4° C to prevent evaporation.
106 4. Mitomycin C (Fluka, Buchs, Switzerland) is dissolved in Iscove's medium (Sigma) at 1
107 mg/mL, stored at 4° C and then added to the cultures as required.
108 5. Triple Select (GIBCO, Invitrogen) is used instead of trypsin to detach cells from the tissue
109 culture plates.
110 6. DPBS without Ca²⁺ or Mg²⁺, pH 7.4 (GIBCO, Invitrogen).
111 7. Trypan Blue (Sigma) to count and evaluate cell viability (*see Note 2*).
112 8. Neubauer haemocytometer (Brand, Wertheim, Germany).

113 **2.2. Derivation of Conditioned Media**

114 As previously described (17), TERS1 medium is usually used as the base media for human
115 foreskin fibroblast conditioning, using passage 11 to 18 cells.

- 116 1. TERS1 conditioned media: after collection media can be frozen at -80° C for up to 6 months
117 (*see Notes 3 and 4*).

118 **2.3. Preparation of Human Functional Foreskin-derived Extracellular Matrix (hffECM)**

- 119 1. Osmotic lysis buffer Tris-EDTA (TE) pH 7.4: 10mM TrisHCl pH 7.4, 1mM EDTA pH 8 (all
120 from Sigma). For preparation details *see Note 5*.
121 2. Cell scrapers (Falcon, BD Biosciences, Madrid).
122 3. DPBS (GIBCO, Invitrogen).

123 **2.4. Preparation of Samples for Transmission Electron Microscopy (TEM)**

- 124 1. PB (EMS).

- 125 2. Glutaraldehyde (3%): dilute glutaraldehyde (Electron Microscopy Science [EMS], Hattfield,
126 PA) from a 25% (v/v) stock in PB.
127 3. Petri dish (Falcon, BD).
128 4. Disposable Pasteur pipettes (Falcon).
129 5. Osmium 1% (Sigma): prepared by diluting osmium in PB.
130 6. Uranyl acetate (2%) diluted in 70% ethanol.
131 7. Preparation of alcohol gradient: use the appropriate volume of absolute ethanol (Merck), mixed
132 with distilled water to prepare 30%, 50%, 70%, and 90% ethanol solutions.
133 8. Resin LR-White (EMS).

134 *See Note 6* for safety measures that must be adopted to perform this technique.

135 **2.5. Preparation of Samples for Atomic Force Microscopy (AFM)**

- 136 1. 0.1 M PBS (Gibco)
137 2. 2% paraformaldehyde/2.5% glutaraldehyde/PB (all from EMS).
138 3. Series of ethanol/water solutions (30%, 50%, 70%, 90%, 96%). All from Sigma.
139 4. Absolute ethanol (Sigma).

140 **2.6. Culture and Maintenance of Undifferentiated hESC lines**

- 141 1. H9 and H1 hESC lines (WiCell, Madison, WI).
142 2. TERS1 conditioned media.
143 3. TGF- β 1 (Invitrogen): reconstituted with sterile 4 mM HCl (Sigma) containing 1 mg/mL of
144 human serum albumin (Sigma) to a final stock solution concentration of 40 ng/mL. Store in 50
145 μ L aliquots at -20° C.
146 4. Human recombinant basic fibroblast growth factor (bFGF; Invitrogen) is dissolved in 1 mL
147 DMEM Knockout Medium (Invitrogen) and stored in 100 μ L aliquots at -20° C.

148 **2.7. Analysis of Undifferentiated hESC Markers**

149 **2.7.1. Staining of Pluripotency Cell Surface Markers by Immunocytochemistry**

150 Antibodies that detect specific cell-surface hESC markers are commercially available from
151 Chemicon and antibodies for detection of the ECM component fibronectin are available from
152 Sigma. Secondary antibodies are all commercially available from Invitrogen. *See Tables 1 and 2*
153 for recommended dilutions and providers.

- 154 1. DPBS without Ca²⁺, Mg²⁺ (GIBCO, Invitrogen).
155 2. 4% paraformaldehyde (*see* recipe at 2.7.2.2).
156 3. 0.05% sodium azide (Sigma) in DPBS.

157 4. Triton-X-100 (Sigma): prepare a dilution of 1% Triton-X-100 in DPBS to permeabilize the
158 hESCs.

159 5. Blocking solution: 4% serum in DPBS. Serum for the blocking solution should be of the same
160 origin/animal as the secondary antibody.

161 6. Prolong gold anti-fade reagent with DAPI (Invitrogen). *See Note 7.*

162 *2.7.2. Alkaline phosphatase (AP) detection kit (Chemicon Millipore, Billerica, MA)*

163 1. This kit provides two components for AP detection: Fast Red Violet solution (0.8 g/L stock)
164 and naphthol AS-BI phosphate solution (4 mg/mL) in AMPD buffer (2 mol/L), pH 9.5.

165 2. Paraformaldehyde 4% in PBS: Prepared fresh with distilled water. To prepare 100 mL, heat 50
166 mL distilled water to 60° C on a hot plate in a fume hood (do not exceed 65° C) and add 4 g of
167 paraformaldehyde powder. Stir the solution until it becomes clear (a few drops of NaOH can be
168 added). After that, filter the solution through a 0.22 µm filter and add 50 mL of sterile PBS at pH
169 7.4 (*see Note 8*).

170 3. TBST 1× Rinse Buffer: prepared fresh with 20 mM Tris-HCl, pH 7.4, 0.15M NaCl, 0.05%
171 Tween-20 (all from Sigma).

172 *2.7.3. Intracellular Markers by RT-PCR and QPCR Analysis*

173 *See Table 3* for the complete list of primers and reaction conditions.

174 1. RNeasy mini kit (74104, Qiagen).

175 2. Deoxyribonuclease (DNase) I (RNase-free DNase SET; 79254; Qiagen).

176 3. High Capacity cDNA RT kit (PN 4368814; Applied Biosystems).

177 4. FastStart PCR Master (04710436001; Roche).

178 5. Power SYBR® Green PCR master mix (4367659; Applied Biosystems).

179 6. PCR microplates.

180 7. 1.5 mL sterile microcentrifuge tubes (Eppendorf, Hamburg, Germany).

181 8. Absolute ethanol (Merck, Darmstadt, Germany).

182 9. Standard table-top microcentrifuge capable of 13,000 × g centrifugal force.

183 10. Standard thermal cycler.

184 11. NanoDrop spectrophotometer or similar to evaluate the synthesized cDNA quality.

185 *2.7.4. Telomerase Activity*

186 1. TRAPEZE Telomerase Detection Kit (Chemicon, Billerica, MA).

187 2. PBS without Ca²⁺, Mg²⁺ (GIBCO).

188 3. 10--20% nondenaturing polyacrylamide precasted gels.

189 4. 10× TBE (BioRad, Hercules, CA).

- 190 5. SYBR green (Molecular Probes).
191 6. Loading buffer 10× (BioRad).
192 7. Nondenaturing 10--20% polyacrylamide gel (15% precasted gels from BioRad).

193

194 **3. Methods**

195 Extracellular matrix compounds play important roles in cell adhesion, attachment, cell
196 interactions, and proliferation (**18,11**). Previous studies have demonstrated that the components
197 of ECM support undifferentiated growth of hESCs. Extracellular matrix is generally organized
198 into a three-dimensional fibrous structure and therefore, it is crucial to extract the ECM samples
199 from human fibroblasts rapidly and at 4° C which prevents conformational changes and protein
200 degradation. Transmission electron microscopy (TEM) and AFM can be used to assess the
201 integrity of hffECM after the obtention. To validate functionality, it is very important to evaluate
202 the ability of the extracted ECM to maintain hESCs in the undifferentiated state. This can be
203 assessed by long-term growth of hESCs on this ECM and by routine analysis of pluripotency
204 using the following assays: RT-PCR, immunocytochemistry, determination of alkaline
205 phosphatase, and telomerase expression and analysis of spontaneous differentiation ability (**19**).

206 **3.1. Preparation of Fibroblast Cells and Conditioned Media**

- 207 1. Human foreskin fibroblasts are grown in Iscove's Medium and the cells are split using Triple
208 Select every 5--7 days.
209 2. When confluent, the cells were inactivated using mitomycin C at 37°C in an incubator with 5%
210 CO₂ for 3 h.
211 3. They are then washed with DPBS three times (5 min), digested, and counted (*see Note 2*).
212 4. Seed fibroblast at a density of 6×10⁶ cells in a T75 flask coated with 0.1% gelatine, and culture
213 at 37°C with 5% CO₂ for 24 h before adding TERS1 medium.
214 5. TERS1 conditioned medium is collected every day until day 7, and stored at -80°C for up to 6
215 months (*see Notes 3 and 4*).

216 **3.2. Preparation of Extracellular Matrix (ECM)**

- 217 1. Human foreskin fibroblasts are grown in an appropriate medium and the cells are split using
218 Triple-select every 5--7 days. When the cells reach 100% confluence, they are inactivated by
219 treatment with mitomycin C (10µg/mL) for 3 h, and then washed three times with DPBS.
220 2. Cells are detached, counted and seeded (2×10⁵ cells/per well) in a six-well plates, coated with
221 0.1% gelatin, and cultured at 37°C and 5% CO₂ for 24 h.
222 3. Inactivated cell cultures are maintained for 7--8 days, with a media change every second day.

- 223 4. Foreskin cultures are treated on day 7, following the recommendations described in (15).
- 224 5. Cells are washed twice with DPBS without Ca^{2+} and Mg^{2+} and subsequently lysed by osmotic
- 225 shock with Tris EDTA buffer (10 mM Tris, 1 mM EDTA, PH 7.4) adding, 1.5 mL per 10^6 cells.
- 226 6. After addition of osmotic shock buffer, cells are incubated o.n. at 4°C using an orbital shaker,
- 227 after which time the Tris-EDTA buffer is removed by aspiration (*see Note 9*).
- 228 6. Lysed cells are eliminated from the plates by rinsing six times (5 min each) with DPBS. Plates
- 229 containing the remaining hffECM are stored at 4°C or dried and sterilised using standard
- 230 methods. Examples of foreskin fibroblast cells and ECM samples studied using TEM are shown
- 231 in **Fig. 1A**.

232 **3.3. Preparation of Samples for TEM** (*see Notes 6 and 10 when Planning these Experiments*)

- 233 1. Wash samples twice with PBS for 2--3 min.
- 234 2. Fix for 30 min at 37°C with 3% glutaraldehyde. Add glutaraldehyde carefully until the plate
- 235 surface is totally covered.
- 236 3. Incubate for 30 min and store at 37°C , keeping the samples inside a box or Petri dish to avoid
- 237 release of carcinogenic vapor.
- 238 4. Aspirate glutaraldehyde with a disposable Pasteur pipette and discard adequately.
- 239 5. Wash 3--4 times for 3 min with PBS.
- 240 6. Cover the samples with PBS and maintain them at 4°C (*see Note 11*).
- 241 7. Fixation and contrasting: add 1 mL of 2% osmium to cover the plates and leave for 1 h.
- 242 8. Wash three times (5 min each) with distilled water at 4°C (do not exceed 15 min).
- 243 9. Dehydration procedure (all steps are performed at 4°C):
- 244 9.1. Add 30% alcohol for 5 min.
- 245 9.2. Wash with 50% alcohol (10 min) at 4°C (exceeding this time can cause protein
- 246 damage).
- 247 9.3. Wash twice with 70% alcohol (10 min each).
- 248 10. Add 1 mL of 2% uranyl acetate in 70% alcohol and incubate for 2 h at 4°C .
- 249 11. Continue with the dehydration process by using the following alcohol gradient:
- 250 11.1 Add 70% ethanol 2 times \times (10 min each).
- 251 11.2. Wash with 90% ethanol 2 times \times (10 min each).
- 252 12. To embed the samples in resin, use the following alcohol/LR white resin (EMS) gradient as
- 253 follows:
- 254 12.1. Incubate in 2 parts 90% ethanol: 1part resin for 45 min at RT.
- 255 12.2. Replace the mixture using a Pasteur pipette and discard adequately.

256 12.3. Prepare a dilution 1part 90% ethanol: 2 parts resin, add to the samples and incubate
257 for 45 min.

258 12.4. Remove the mixture and discard appropriately.

259 12.5. Mix 1 part of 100% ethanol and 2 parts resin and incubate for 45 min.

260 12.6. Replace the mixture by adding 100% LR white resin. Incubate o.n. in an orbital
261 shaker.

262 13. To allow polymerization, transfer the samples to an oven and incubate them at 60° C for 24 h.

263 14. Detach and proceed with the sectioning.

264 15. Observe the samples under a transmission electron microscope.

265 **3.4. Atomic Force Microscopy (AFM)**

266 AFM provides detailed 3-dimensional images of ECM protein-surface interactions.

267 1. Samples should be washed in 0.1M PBS and fixed in 2% paraformaldehyde/2.5%
268 glutaraldehyde/PB for 1 h at room temperature.

269 3. Samples are dehydrated using a series of ethanol/water solutions (30%, 50%, 70%, 90%, and
270 96%) for 10 min with final dehydration in absolute ethanol for 10 min twice.

271 3. The dehydrated samples were examined by AFM, operating in the tapped-air mode.

272 4. The ECM protein distribution (on glass) is estimated from AFM images. The amplitude set
273 point should be 1.3 V with a drive amplitude of 300 mV.

274 5. Surface roughness is calculated by processing 10 representative AFM images.

275 Images of glass surfaces with and without hffECM captured using AFM are shown in **Fig. 1B**.

276 **3.5. Growth of Undifferentiated Pluripotent Cells using Feeder-Free Conditions and hffECM**

277 1. Once the ECM-coated plates are ready for use, conditioned medium which has been collected,
278 should be added.

279 2. Add 2 mL of conditioned media containing 50 ng/mL and 100 ng/mL of fresh TGF-β1 and
280 bFGF, respectively. Place the 6-well plates in an incubator at 37° C with 5% CO₂ for at least 3 h
281 before seeding the new hESC colonies.

282 3. Wash the hESC colonies maintained on human feeders twice with prewarmed DMEM
283 medium.

284 4. Dissect hESC colonies mechanically and collect them in a 15 mL polypropylene tube (*see*
285 **Notes 12 and 13**).

286 5. Centrifuge the cells for 3 min at 200 × g and remove the supernatant.

287 6. Gently resuspend the pellet in conditioned medium supplemented with fresh TGF-β1 and
288 bFGF in the same 15 mL tube.

- 289 7. Add 1 mL of media containing 10--20 colonies to each well of the ECM-coated plates.
290 8. Incubate the plates at 37° C with 5% CO₂ and change the media every second day.
291 9. Undifferentiated hESCs should be transferred to new plates every 5--7 days and maintained at
292 37° C with 5% CO₂.

293 Examples of contrast phase microscope are shown in **Fig. 2A** and **Fig. 2B**.

294 **3.6. Detection of Cell Surface Pluripotency Markers by Immunocytochemistry**

- 295 1. Remove the culture medium.
296 2. Wash the cells once with DPBS without Ca²⁺ and Mg²⁺. It is important to add the DPBS very
297 gently and not directly to the cells.
298 3. Fix hESCs in 4% paraformaldehyde for 15 min at room temperature by adding 1.5 mL/well to
299 the 6-well plates.
300 4. Wash 4 times with DPBS.
301 5. To permeabilize the hESCs, add 1.5 mL per well of 1% Triton-X-100, followed by an
302 incubation of 10 min at room temperature.
303 6. Wash twice (5 min each) with DPBS.
304 7. Apply 4% of blocking solution at room temperature for 45 min. Serum for the blocking
305 solution should be of the same species as the secondary antibody.
306 8. Remove the blocking solution but do not wash the cells.
307 9. Dilute the primary antibody blocking solution (*see Table 1*).
308 10. Add 1 mL of the corresponding primary antibody dilution to the cultures for at least 1 h at RT
309 or overnight at 4° C.
310 11. Wash 3 times with DPBS. Cells can be left overnight before adding the secondary antibody.
311 12. Dilute the secondary antibody in DPBS and add 1 mL per well (*see Table 2*).
312 13. Incubate at room temperature for 60 min and in darkness as exposure to light may cause
313 bleaching of fluorescent labels.
314 14. Wash the cells 4 times with DPBS.
315 15. If the cells are attached to a coverslip mount it on a slide using prolong gold antifade reagent
316 with DAPI. Remove any bubbles that may have formed during mounting.
317 16. Let the slides dry for 15 min in conditions where they are protected from light.
318 17. After 90 min the samples can be observed using a fluorescence microscope. Examples of the
319 morphology and undifferentiated hESC surface markers grown on plastic dishes coated by ECM
320 derived from human fibroblasts and in the presence of conditioned medium are presented in **Fig.**
321 **2C,D** and **3**.

322 **3.7. Preparation of Samples for RT-PCR and QPCR Analysis**

323 Analyzes of mRNA expression by reverse transcription PCR (RT-PCR) and real-time
324 quantitative PCR (QPCR) are carried out using standard protocols. An RT-PCR reaction is
325 performed at 60° C and for 35 cycles, except for β 2-microglobulin (performed at 55° C for 35
326 cycles). The QPCR reaction is performed at 60° C (60 s) and 95° C (15 s) for 40 cycles. Primer
327 sequences were designed using Primer3 software and synthesized by Sigma-Aldrich. All primer
328 sequences and DNA fragments are listed in **Table 3**. Transcripts encoding the following proteins
329 Oct-4, Tert, Nanog, and FoxD3 should be assessed for pluripotency, and AFP, DBH, and CAC
330 for differentiation (specific lineage) markers. The β 2-microglobulin gene is used as an
331 endogenous control (housekeeping) gene.

332 **3.7.1. Extraction and Quantification of Total RNA**

333 Total RNA extraction can be performed using 20 hESC colonies maintained on ECM. As a
334 positive control, undifferentiated hESCs maintained on feeder cells should be used. We use the
335 RNeasy mini kit (74104; Qiagen) following provider-recommended instructions with some
336 modifications. To eliminate contamination by genomic DNA, the initial RNA pellet was
337 incubated with deoxyribonuclease (DNase) I (RNase-free DNase SET; 79254; Qiagen).

- 338 1. Cut the cells from the culture dish with a needle and collect them in a centrifuge tube.
- 339 2. Add 350 μ L of buffer RLT and vortex for 1 min.
- 340 3. Centrifuge the lysate for 3 min at maximum speed. Carefully remove the supernatant by
341 pipetting out and discarding it.
- 342 4. Add 1 volume of 70% ethanol to the homogenized sample and mix well by pipetting only (do
343 not centrifuge). The volume might be less than 350 μ L due to loss during the homogenization
344 process. The use of ethanol can trigger precipitates to form; however, their presence has no
345 impact on the process.
- 346 5. Transfer up to 700 μ L from the sample, including any precipitates, to an RNeasy mini spin
347 column (pink) placed in a 2 mL collection tube, and close the lid.
- 348 6. Centrifuge at 8,000 \times g (10,000 rpm) for 15 s, discard the flow-through and reuse the
349 collection tube for step 7. Note: if the sample volume is greater than 700 μ L, the aliquots must be
350 centrifuged one after the other in the same column, discarding the flow-through after each
351 centrifugation.
- 352 7. Add 350 μ L RW1 buffer to the RNeasy mini spin column, close the lid, and centrifuge at 8,000
353 \times g (10,000 rpm) for 15 s. Discard the flow-through and reuse the collection tube for step 10.

- 354 8. Add 10 μL DNase I stock solution to 70 μL RDD buffer. Mix by gently inverting the tube;
355 centrifuge briefly to collect the liquid from the tube walls.
- 356 9. Add DNase I to the incubation mix (80 μL) and transfer it directly to the RNeasy column
357 membrane, and it place on the benchtop at 20--30°C for 15 min.
- 358 10. Add 350 μL RW1 buffer to the RNeasy mini spin column, close the lid, and centrifuge at \geq
359 8,000 $\times g$ for 15 s. Discard the flow-through.
- 360 11. Add 500 μL RPE buffer to the RNeasy mini spin column, close the lid, and centrifuge at \geq
361 8,000 $\times g$ for 15 s. Discard the flow-through and reuse the collection tube.
- 362 12. Add 500 μL RPE buffer to the RNeasy mini spin column, close the lid, and centrifuge at \geq
363 8,000 $\times g$ for 2 min to wash the column membrane.
- 364 13. Place the RNeasy mini spin column in a new 2 mL collection tube and centrifuge at full speed
365 for 1 min to dry the membrane (optional step).
- 366 14. Place the RNeasy mini spin column in a new 1.5 mL collection tube and add 30--50 μL
367 RNase-free water directly to the spin column membrane. Close the lid, and centrifuge at \geq 8,000
368 $\times g$ for 1 min to elute the RNA.
- 369 15. If the expected RNA yield is $>30 \mu\text{g}$, repeat step 14 using another 30--50 μL RNase-free
370 water, or the elute from **step 14** (if a high RNA concentration is required). Reuse the collection
371 tube from **step 14**. Note: if the elute from **step 14** is used, the RNA yield might be 15--% lower
372 than using a second volume of RNase-free water but the final RNA concentration will be higher
373 (*see Note 14*).
- 374 16. Quantify the extracted RNA and evaluate its quality using a NanoDrop spectrophotometer or
375 a RNA-integrity gel. Either use the eluted RNA directly in following steps (RT-PCR and QPCR)
376 or store the eluted RNA at -80° C for later analysis.

377

378 **3.7.2. cDNA Synthesis**

379 Use 50 μL from each sample obtained for total RNA to single-stranded cDNA reverse
380 transcription (RT). We follow the recommendations from the High Capacity cDNA RT kit (PN
381 4368814, Applied Biosystems).

382 1. Place the 2 \times RT master mix on ice and mix gently.

383 2. Pipette 25 μL of 2 \times RT master mix into each well of an individual tube (*see Note 15*).

384 3. Pipette 25 μL of RNA sample into each well, pipetting up and down two times to mix (*see*
385 **Note 16**).

- 386 4. Seal the tubes and briefly centrifuge them to spin down the contents and to eliminate any air
387 bubbles.
- 388 5. Place the plate or tubes on ice until you are ready to load them into the thermal cycler.
- 389 6. Program the thermal cycler conditions with the following parameter steps: (i) step 1: 25 ° C for
390 10 min; (ii) step 2: 37 ° C for 120 min; (iii) step 3: 85 ° C for 5 min; (iv) step 4: 4 ° C for
391 indefinite time.

392 7. Set the reaction volume to 20 µL.

393 8. Load the reactions into the thermal cycler and start the reverse transcription run.

394 9. Quantify the synthesized cDNA and evaluate its quality using a NanoDrop spectrophotometer
395 or cDNA integrity gel.

396 **3.7.3. PCR Analysis**

397 Use a 50 µL reaction per sample to obtain the PCR products. We follow the recommendations
398 from FastStart PCR Master (04710436001; Roche).

399 1. Prepare the microplates for PCR according to the instrument instructions.

400 2. Thaw the solutions and briefly spin the vials in a microcentrifuge before opening.

401 3. Mix the solutions by pipetting them up and down gently and store them on ice.

402 4. Prepare 10× concentration solutions of the PCR primers (see **Table 3**)

403 5. Prepare a PCR mix for the number of reactions to be run plus one additional reaction. The PCR
404 mix contains the following products for each reaction in the following order: 25 µL 2× master
405 mix, 5 µL forward primer (3 µM), 5 µL reverse primer (3 µM), and 10 µL PCR-grade water.

406 6. Mix the solution by pipetting it up and down (do not vortex).

407 7. Transfer 45 µL PCR mix into each reaction well of the PCR microplate.

408 8. Add 5 µL of template DNA (up to 100 ng cDNA) into each reaction well.

409 9. Prepare the microplate for the PCR reaction according to the instrument's instructions.

410 10. Program the thermal cycler conditions with following steps: (i) step 1: 1 cycle at 95° C for 4
411 min; (ii) step 2: 30 to 40 cycles at 95° C for 30 s, and 45--65° C for 30 s, and 72° C for 45--180 s;
412 (iii) step 3: 1 cycle at 72 ° C for 7 min; (iv) step 4: 4° C for an indefinite time.

413 7. Set the reaction volume to 50 µL.

414 8. Load the microplate into the thermal cycler and start the PCR reaction.

415 The results can be observed in the electrophoresis gels on **Fig. 4B** and **Fig. 4C**.

416 **3.7.4. QPCR Analysis**

417 1. Completely thaw the Power SYBR Green PCR Master Mix and gently mix the reagents.

- 418 2. In polypropylene tubes, prepare the PCR reagent mix for the desired number of PCR
- 419 reactions. Each 20 μ L PCR reaction contains 10 μ L of the PCR Master Mix, 50--300 nM from
- 420 each primer, 100 ng template, and a variable quantity of nuclease-free water (*see Note 17*).
- 421 3. Mix gently (do not vortex) and centrifuge briefly.
- 422 4. Prepare the microplate for the QPCR reactions according to instrument's instructions.
- 423 5. Program the thermal cycler conditions with the following steps: (i) step 1: 1 cycle at 95° C for
- 424 4 min; (ii) step 2: 30 to 40 cycles at 95° C for 30 s, 45--65° C for 30 s, and 72° C for 45--180 s;
- 425 (iii) step 3: 1 cycle at 72 ° C for 7 min; (iv) step 4 at 4 ° C for an indefinite time.
- 426 6. Set the rest of the thermal cycler parameters (e.g., volume = 20 μ L) following instrument
- 427 user's manual to configure the plate documentation details.
- 428 7. Load the microplate into the thermal cycler and start the PCR reaction.
- 429 8. Analyze and export the results using a spreadsheet program with statistical features.
- 430 9. Calculate the average cycle time, the standard deviation, and the coefficient of variation for
- 431 each group of replicates of any sample. Remove outlier points ($C_t > 0.3 \times$ standard deviation).
- 432 10. Apply the $\Delta\Delta C_t$ method to obtain "fold changes" as desired output (**20**). The internal control
- 433 selected is β -2 microglobulin gene.

434 **3.8. Telomerase activity assay**

435 Telomerase activity is assayed using telomeric repeat amplification protocol using the Trapeze
436 Kit (Chemicon) and according to the manufacturer's protocol but with some modifications.

437 *3.8.1 Sample Preparation*

- 438 1. For stem cell analysis, collect 30--100 colonies. Pellet cells at 400 \times g for 5 min at 4° C. We
- 439 highly recommend that the positive and negative controls provided with the kit and a negative
- 440 control (a differentiated cell line and/or heat inactivated immortal/stem cells) be used.
- 441 2. Wash cell pellet with sterile Ca^{2+} and Mg^{2+} free PBS for 5 min at 400 \times g at 4° C.
- 442 3. Resuspended the cell pellet with 5--20 μ L CHAPS lysis buffer (Thermo Scientific) for stem
- 443 cell colonies.
- 444 4. Place on ice for 30 min.
- 445 5. Pellet cells at high speed (12,000 rpm) at 4° C for 20 min.
- 446 6. Transfer the supernatant to a new tube. At this point the supernatants are kept at -80° C and can
- 447 be stored for up to one year to be used for telomerase detection.

448

449 *3.8.2 PCR reaction*

- 450 1. Use 2--4 μ L of sample per PCR reaction.

451 2. Heat inactivated negative controls must be subjected to 85° C for ten min. Then use the same
452 2--4 µL volume for the PCR reactions.

453 3. Prepare a master mix containing all these components except the templates, all the reagents are
454 provided by the kit except Taq polymerase:

- 455 • 10× TRAP Reaction buffer 5 µL
- 456 • 50× dNTP mix 1 µL
- 457 • TS primer 1 µL
- 458 • TRAP primer mix 1 µL
- 459 • Taq polymerase (5 U/µL) 0.4 µL
- 460 • dH₂O 29.5 µL
- 461 • Template 2 µL

462 4. PCR program

- 463 • 1 cycle: 30° C 30 min
- 464 • 30--33 cycles: 94° C 30 s
- 465 59° C 30 s

466 3.8.1 Separation by Electrophoresis

467 1. For sample electrophoresis, use a 10--15 µl PCR reaction with a 2--5 µl loading buffer 10×
468 (BioRad).

469 2. Load a nondenaturing 10--20% polyacrylamide gel (we use 15% precasted gels from BioRad).

470 3. Run the gel in TBE 0.5X until both color bands are out of the gel.

471 4. Prepare the SYBR green solution (1/10,000) in TBE 1X.

472 5. Stain the gel for 15--20 min in the dark.

473 6. Visualize the bands in a transilluminator (with the same wavelength as the ethidium bromide).

474 The results for telomerase activity are presented in **Fig. 4D**.

475

476 4. Notes

477 1. Conditioned media can be prepared using foreskin fibroblasts between passages 11--18, but in
478 order to maintain the quality, we recommend that cells between passages 11 to 16 be used.

479 2. Cell counting: take 20 µL of cell suspension and dilute it with 70 µL of culture medium. Add
480 10 µL of Trypan Blue solution (Sigma), mix, and incubate for 1 min before counting viable

481 (round, clear cells) and nonviable (blue) cells using a Neubauer haemocytometer and plate 6×10^6

Growth of hPSCs using functional hECM

482 cells per flask or 2×10^5 cells per well for 75 cm² flasks and 6-well plates respectively. More
483 than 75% of cells should be viable.

484 3. Before using of conditioned TESR1 medium, add 100 ng/mL of bFGF and 50 ng/mL of TGF-
485 β 1. Conditioned medium can be kept at +4°C for 1 week or stored at -80° C for 6 months.

486 4. No differences between frozen and fresh conditioned media have been observed.

487 5. Lysis buffer preparation. The following is an example for 250 mL:

- 488 • 2.5 mL 1 M Tris-HCl pH 7.4
- 489 • 500 μ L 0.5 M EDTA pH 8.0
- 490 • 247 mL H₂O

Stock Solutions:

492 ○ 1 M Tris-Cl, pH 7.4 (1 L):

- 493 ■ 121 g Tris Base
- 494 ■ 1 L H₂O

495 *Adjust pH*

496 ○ 0.5 M EDTA (1 L):

- 497 ■ 186.1 g EDTA Na₂H₂O
- 498 ■ 1 L H₂O

499 *Adjust pH*

500

501 6. TEM inclusion procedure: Glutaraldehyde is carcinogenic by inhalation, it is important to
502 manipulate it in a fume hood. During the 37° C incubation it is very important to avoid inhaling
503 these fumes, keeping the culture plates inside a petri dish in the special stove. Osmium is
504 carcinogenic and toxic by inhalation and contact and so double gloves and a mask should be
505 worn, in addition to working under fume hood. Uranyl acetate is carcinogenic and radioactive.
506 Manipulation must be performed in an adequate installation under fume hood using double
507 gloves and a mask. Given their toxicity, those residues need to be manipulated and discarded
508 properly.

509 7. Try to avoid bubbles in the samples.

510 8. Do not use until the solution reaches room temperature and adjust the pH if necessary.

511 9. We have also performed this process by incubating with ice in the orbital shaker for 2.5 hours.

512 10. When planning to do TEM analysis, the seeding of hFFs, the cell lysis and subsequent
513 pluripotent cell seeding needs to be done on Permanox® chambers.


514 11. At this point, the plates can be maintained for several days at 4°C by adding sodium azide.

- 515 12. hESCs were cultured and maintained as previously described (21). Cells were passaged
516 mechanically and re-plated on ECM-coated plates.
- 517 13. The optimal size of hESCs before the splitting procedure is when the colonies completely
518 cover the magnification field (x10).
- 519 14. If you use the elution obtained in step 10, the quantity of RNA obtained may be 15--30% less
520 than using RNase-free water.
- 521 15. The kit reagents must always be thawed on ice.
- 522 16. Use up to 5 µg of total RNA per 50 µL RT reaction.
- 523 17. Include an extra volume to account for pipetting losses.

524 **Acknowledgements:**

525 The authors would like to thank Dr. Deborah Burks, Dr. Sonia Prado, Dr. X. Chen Xiong, Mrs.
526 Vanessa Blanca, Dr. Angel Ayuso-Sacido, and Petra Stojkovic for their support. This work was
527 supported by funds for research in the field of Regenerative Medicine from the Regional
528 Government Health Department (Generalitat Valenciana); the Instituto Carlos III belongs to the
529 Spanish Ministry of Health and Consumer Affairs. Drs. Carmen Escobedo-Lucea and Andres
530 Sanz-Garcia are financed by Academy of Finland projects as follows: No. 273689 (Research
531 Fellow), No. 266486 (FINSKIN), No. 276371 (VATURP), and No. 278153 (mobility grant).
532

533

Figure Captions

534

535 **Fig. 1.** Transmission electron microscopy (TEM) and atomic force microscopy (AFM) of the
 536 hffECM after the extraction to evaluate structural integrity and roughness. (A) Ultrastructural
 537 analysis of the efficiency of the extraction protocol using TEM. Plates of lysed cultures and their
 538 respective controls with intact foreskin fibroblasts were fixed and processed for TEM
 539 ultrastructural analysis. Human foreskin fibroblasts (hFFs) were maintained for the indicated
 540 times and then subjected to hypotonic lysis. (A.1 and A.3) Semi-thin sections were prepared from
 541 control and lysed cultures and were stained with toluidine blue. (A.2) Representative TEM image
 542 of intact hFF control cells after 7 days in culture. (A.4) Representative TEM image of lysed
 543 culture plate after 7 days in culture. Scale bars, 200 μm (A.1 and A.3), 1 μm (A.2), 500nm (A.4).
 544 (B) AFM analysis of ECM conformation on glass surfaces. The images show the amplitude mode
 545 with the same scale. (B.1) The smallest roughness corresponds to fibronectin that was used as

546 experimental control. The mean surface roughness observed demonstrates that the surface
547 roughness is significantly lower on day 1 (B.2) than after hFFs culture on day 2 (B.3). Scale bars
548 250 nm (Figures 1.A.1 and 1.A.3 reproduced from (12) with permission from Springer).

549

550


551

552

553


554

555




556
557 **Fig. 2.** (A and B) Morphology of undifferentiated hESCs grown for 11 passages over feeder cells
558 and on plastic coated with hffECM using conditioned media respectively. (C and D) Images
559 showing alkaline phosphatase activity in both feeder and hffECM conditions, indicating
560 maintenance of pluripotency. Images were obtained using Zeiss Axiovert 200M microscope
561 (magnifications $\times 100$).

562



563
 564 **Fig. 3.** Morphology and cell surface markers of undifferentiated hESC grown for 11 passages on
 565 plastic dishes coated with hffECM derived from human fibroblasts and in the presence of
 566 conditioned medium. Note round and compacted hESC colonies. The presence of SSEA4 (A--C,
 567 magenta), Tra1-81 (D--F, green), Tra1-60 (H--J, green), pluripotency markers were observed.
 568 Note the presence of specific fibronectin staining (G--J and R-U).
 569 Morphology and cell surface markers of undifferentiated hESCs grown for 11 passages over hFFs
 570 feeder. The presence of SSEA4 (K--M, magenta), TRA-1-81 (O--K, green), TRA-1-60 (S--U,
 571 green), pluripotency markers were observed. Note the presence of specific fibronectin staining (G
 572 and J). Images were obtained using confocal microscope (10× magnifications).

573



574
 575 **Fig. 4.** Analysis of specific molecular hESC markers and telomerase activity. hESCs were grown
 576 on hffECM and in the presence of conditioned medium for 11 passages. Controls over foreskin
 577 feeder were also and grown at the same time. (A) QPCR comparing expression of pluripotency
 578 and differentiation genes in cells maintained on hffECM and hFF. The expression of
 579 characteristic pluripotent markers is higher in the cells maintained on hffECM than on hFF. This
 580 indicates that our system is highly selective and only cells with the best quality are able to adapt
 581 and survive. No expression of differentiation markers (AFP, DBH and CAC) was detected. (B
 582 and C) Cells maintained on hffECM and foreskin feeders respectively. Line 1 and 10: Ladders
 583 with 1Kb; 2. Corresponds to negative control; 3. Housekeeping gene β -2 microglobulin. Cells
 584 express all the typical hESC markers 4. Nanog; 5. Oct-4; 6. Tert; 7. FoxD3. After 11 passages on
 585 ECM the cells were negative for differentiation markers AFP and CAC (lines 8 and 9,
 586 respectively. (D) Colonies retained telomerase activity after 11 passages on hffECM (line 3).
 587 Line 4 corresponds to their H9 counterparts maintained 11 passages over foreskin feeder cells.
 588 Line 1 and 6 are negative controls, and the line 2 the positive control.

589

590 **Table**

591

592 **Table 1.** List of primary antibodies

593

594

Primary antibody	Isotype	Working dilution	Catalogue number	Provider
SSEA4	IgG3	1:100	MAB 4304	Chemicon
Tra1-81	IgM	1:100	MAB 4381	Chemicon
Tra1-60	IgM	1:100	MAB 4360	Chemicon
Fibronectin	IgG1	1:100	F0916	Sigma

595 *SSEA4, Tra1-81, Tra1-60, and AP can also be acquired as a kit (SCR001; Chemicon).

596

597

598

599

600

601

602

603

Accepted Manuscript

604

605 **Table 2.** List of secondary antibodies

606

Secondary antibody	Working dilution	Catalogue number	Provider
Alexa Fluor goat against IgG	1:500	A11029	Invitrogen
Alexa Fluor against IgM	1:500	A21042	Invitrogen
Alexa Fluor against IgG1	1:500	A21124	Invitrogen

607

608

609

610

611

Accepted Manuscript

612
613
614
615**Table 3.** List of primers and conditions used for both RT-PCR and qPCR

Gene Name	Primer Sequences	Annealing Temperature (° C)	Size (bp)	Detection
Housekeeping gene				
β2-microglobulin	F: CTCGCGCTACTCTCTCTTTCTG R: GCTTACATGTCTCGATCCCCT	55	335	RT-PCR QPCR
Pluripotency assay genes				
Nanog	F: GGTGGCAGAAAAACAACACTGG R: CATCCCTGGTGGTAGGAAGA	60	235	RT-PCR
Nanog	F: AATGGTGTGACGCAGAAGG R: ACTGGATGTTCTGGGTCTGG	60	157	QPCR
Oct-4	F: cctgtctccgtcaccactct R: CAAAAACCTGGCACAACCT	60	128	RT-PCR QPCR
FoxD3	F: CAGAGCCCGCAGAAGAAG R: CGAAGCAGTCGTTGAGTGAG	60	133	RT-PCR
FoxD3	F: GCCCAAGAACAGCCTAGTGA R: GGGTCCAGGGTCCAGTAGTT	60	254	QPCR
Tert	F: GACCTCCATCAGAGCCAGTC R: CGCAAGACCCCAAAGAGTT	60	84	RT-PCR
Tert	F: GCGTTTGGTGGATGATTTCT R: AGCTGGAGTAGTCGCTCTGC	60	254	QPCR
Differentiation assay genes				
AFP	F: TCGGTTTCTCGTTGCTTACA R: GCTGCCATTTTTCTGGTGAT	60	81	RT-PCR
AFP	F: Acacaaaaagcccactccag R: ggtgcatacaggaagggatg	60	147	QPCR
DBH	F: tgactgggagaaaggtggtc R: tacgtgcaggaggtgatgag	60	160	QPCR
CAC	F: tgctgatcgtatgcagaagg R: gctggaaggtggacagagag	60	135	RT-PCR QPCR

616
617
618
619

620 **References:**

- 621 1. Takahashi K, Okita K, Nakagawa M et al. (2007) Induction of pluripotent stem cells from
622 fibroblast cultures. *Nat Protoc* **2** (12), 3081--3089
- 623 2. Takahashi K, Tanabe K, Ohnuki M et al. (2007) Induction of Pluripotent Stem Cells from
624 Adult Human Fibroblasts by Defined Factors. *Cell* **131** (5), 861--872
- 625 3. Klimanskaya I, Chung Y, Meisner L et al. (2005) Human embryonic stem cells derived
626 without feeder cells. *Lancet* **7** (13), 1636--1641
- 627 4. Xu C, Inokuma M, Denham J et al. (2001) Feeder-free growth of undifferentiated human
628 embryonic stem cells. *Nat Biotechnol* **19** (10), 971--974
- 629 5. Cyranoski D (2014) Next-generation stem cells cleared for human trial. *Nature*,
- 630 6. Schwartz SD, Regillo CD, Lam BL et al. (2014) Human embryonic stem cell-derived retinal
631 pigment epithelium in patients with age-related macular degeneration and Stargardt's macular
632 dystrophy: follow-up of two open-label phase 1/2 studies. *The Lancet*,
- 633 7. Martin MJ, Muotri A, Gage F et al. (2005) Human embryonic stem cells express an
634 immunogenic nonhuman sialic acid. *Nature Medicine* **11**, 228--232
- 635 8. Kagami S, Kondo S, Löster K et al. (1998) Collagen type I modulates the platelet-derived
636 growth factor (PDGF) regulation of the growth and expression of beta1 integrins by rat mesangial
637 cells. *Biochem Biophys Res Commun* **252** (3), 728--732
- 638 9. Sjaastad MD, Nelson WJ (1997) Integrin-mediated calcium signaling and regulation of cell
639 adhesion by intracellular calcium. *Bioessays* **19**, 47--55
- 640 10. Schuppan D, Cramer T, Bauer M et al. (1998) Hepatocytes as a source of collagen type XVIII
641 endostatin. *Lancet* **352**, 879--880
- 642 11. Cukierman E, Pankov R, Stevens DR et al. (2011) Taking cell-matrix adhesion to the third
643 dimension. *Science* **294** (5547), 1708--1712
- 644 12. Escobedo-Lucea C, Ayuso-Sacido A, Xiong C et al. (2012) Development of a human
645 extracellular matrix for applications related with stem cells and tissue engineering. *Stem Cell Rev*
646 **8** (1), 170--183
- 647 13. Grauss RW, Hazekamp MG, Oppenhuizen F et al. (2005) Histological evaluation of
648 decellularised porcine aortic valves: matrix changes due to different decellularisation methods.
649 *Eur J Cardiothorac Surg* **27** (4), 566--571
- 650 14. Escobedo-Lucea C, Stojkovic M (2010) Growth of human embryonic stem cells using
651 derivatives of human fibroblasts. *Methods Mol Biol* **584**, 55--69
- 652 15. Escobedo-Lucea C, Bellver C, Gandia C et al. (2013) A xenogeneic-free protocol for
653 isolation and expansion of human adipose stem cells for clinical uses. *PLoS One* **8** (7), e67870
- 654 16. Prado-Lopez S, Conesa A, Arminan A et al. (2010) Hypoxia promotes efficient
655 differentiation of human embryonic stem cells to functional endothelium. *Stem Cells* **28** (3), 407--
656 418
- 657 17. Ludwig TE, Levenstein ME, Jones JM et al. (2006) Derivation of human embryonic stem
658 cells in defined conditions. *Nat Biotech* **24** (2), 185--187
- 659 18. Werb Z, Chin JR (1998) Extracellular Matrix Remodeling during Morphogenesis. *Ann N Y*
660 *Acad Sci* **857** (1), 110--118
- 661 19. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. (1998) Embryonic stem cell lines derived
662 from human blastocysts. *Science* **6** (282), 1145--1147
- 663 20. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time
664 quantitative PCR and the $2^{-\Delta\Delta C(T)}$ Method. *Methods* **25** (4), 402--408
- 665 21. Stojkovic P, Lako M, Stewart R et al. (2005) An autogeneic feeder cell system that efficiently
666 supports growth of undifferentiated human embryonic stem cells. *Stem Cells* **23** (3), 306--314
- 667
- 668

669

670

Accepted Manuscript